3/29
07:22 am
eq
Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
3/28
08:20 am
eq
Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.
High
Report
Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.
3/27
07:00 am
eq
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
High
Report
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
3/27
07:00 am
eq
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
High
Report
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
2/6
08:37 am
eq
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis [Yahoo! Finance]
High
Report
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis [Yahoo! Finance]
2/6
08:00 am
eq
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
High
Report
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis